CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Symbiotec Pharmalab Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Symbiotec Pharmalab Ltd
385/2, Pigdamber, Rau, Mhow
Phone: +91 7316676405p:+91 7316676405 INDORE, 453331  India Fax: +91 7314201222f:+91 7314201222
Business Summary
Symbiotec Pharmalab Limited is an India-based research and development-driven, science-based pharmaceutical and biotechnology company. The Company operates through three platforms: organic chemistry, biotechnology and complex injectables. It manufactures its products using fermentation and multi-step complex chemical reactions. It has two operational industrial scale active pharmaceutical ingredients (API) manufacturing facilities: Rau, Mhow, Indore (Rau Facility) and Pithampur Special Economic Zone, Madhya Pradesh (SEZ Facility). It has a product portfolio of over 60 corticosteroid and steroidal-hormone APIs that are supplied globally, including Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens and Testosterones. Its Rau Facility- Streoid products include Beclomethasone Dipropionate USP (Micronized & Non-Micronized), Betamethasone Dipropionate, Betamethasone Valerate, USP (Micronized), Clobetasol Propionate USP, Deflazacort Micronized and others.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
Yes--Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20253/31/2025Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Financial Officer RaghavKhandelwal 26 2/4/2022 2/4/2022
Chief Financial Officer RaghavenderRamachandran 2/4/2022 2/4/2022
Company Secretary SalilJain 5/11/2018 5/11/2018
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,752 (As of 6/30/2025)
Outstanding Shares: 61,681,496 (As of 6/30/2025)
Fax Number: +91 7314201222


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 14, 2026